High-dose continuous-infusion ifosfamide in advanced well-differentiated/dedifferentiated liposarcoma
Conclusions
These data suggest that ciHDIFX is active in WD/DDLPS, even in patients already treated with a combination of anthracyclines plus ifosfamide. In this series, ciHDIFX regimen was better tolerated than HDIFX in published studies.
Source: Clinical Sarcoma Research - Category: Cancer & Oncology Source Type: research
More News: Anemia | Cancer & Oncology | Chemotherapy | Liposarcoma | Sarcomas | Study | Thrombocytopenia | Toxicology